microdosing semaglutide schedule GLP-1 Microdosing Explained: A New

In SURMOUNT-1, adults with obesity or overweight without diabetes were randomized to tirzepatide or placebo for 72 weeks

A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets

The addition of GIP seems to: Improve insulin sensitivity Reduce compensatory metabolic slowdown Enhance fat loss, particularly subcutaneous fat By mimicking the natural actions of GLP-1 and GIP, Tirzepatide helps the body respond more efficiently to insulin, slows digestion, and reduces hungerto support steady, sustainable weight loss

The cardiorenal benefits by GLP-1RA may be partially mediated by their effects on glycated hemoglobin level, blood pressure, and other conventional CV risk factors [26, 27]